Lifitegrast is a LFA-1 (lymphocyte function-associated antigen-1) antagonist intended for the treatment of vascular complications of the eye. Lifitegrast is a novel T-cell integrin antagonist that is designed to mimic the binding epitope of ICAM-1. It serves as a molecular decoy to block the binding of LFA-1/ICAM-1 and inhibits the downstream inflammatory process. MW: 615.48. Purity ≥98% by HPLC
Size
5 mg
Concentration
n/a
Applications
n/a
Other Names
(S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid; SAR-1118; SAR 1118; SAR1118; Lifitegrast, Xiidra.